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Devising a cell culture method that maintains human pluripotent stem cells (PSCs) in a state similar to naive
mouse embryonic stem cells (ESCs) has been a much sought after goal in recent years. Here I consider the
historical background to this quest and ask why it is considered consequential.Introduction
A recent flurry of reports has described a
strangely diverse set of endpoints in a
search for what has become something
of a Holy Grail in contemporary stem
cell biology: a cell culture method that
maintains human pluripotent stem cells
(PSCs) in a state similar to that of naive
mouse embryonic stem cells (ESCs).
Here I consider the historical background
to this quest and ask why it is considered
consequential. I assess the methodolo-
gies used to derive and maintain the cells
and the benchmarks used by various in-
vestigators to gauge the success of their
efforts, and I finally place the findings in
the context of recent analyses of pluripo-
tent stem cell populations at the single-
cell level.
The Historical Background
Following a trajectory analogous to that of
research in the mouse, the first human
PSC lines were derived from teratocarci-
nomas. It was apparent from this early
work that human teratocarcinoma-
derived cell lines were different from their
mouse counterparts and from mouse
ESCs. The human cells displayed a
different morphology and an epithelial
phenotype, they expressed a different
set of cell surface markers, they grew
poorly if at all at clonal density, and they
did not respond to Leukemia Inhibitory
Factor (LIF). There were several conceiv-
able explanations for these discrep-
ancies. The human cancer-derived lines
were grossly aneuploid, malignant cells,
and it was possible that they looked and
behaved differently from the mouse cells
due to changes introduced during trans-
formation. Alternatively, it was possible
that the human cells might represent a
different developmental stage to the
mouse ESC lines. Finally, it was possiblethat there were genuine differences in
early embryonic development between
the mouse and human, and the cell lines
would therefore reflect these differences.
The derivation of diploid ESC lines from
the rhesus monkey and human embryo,
which were essentially similar in pheno-
type to human teratocarcinoma, showed
that the differences between primate
and mouse PSCs were unlikely to be a
consequence of the process of malignant
transformation.
The discovery of mouse epiblast stem
cells put a whole new perspective on
this question. Epiblast stem cells, which
are derived from postimplantation mouse
or rat embryos and are similar to the post-
implantation epiblast, in many respects
closely resembled human ESCs. This
finding lent credence to the notion that
perhaps the human cells were not ESCs
at all but really epiblast stem cells that
somehow emerged from the process of
their derivation from the inner cell mass.
The obvious corollary to this interpretation
was that a human equivalent of a bona
fide naive mouse ESC must exist. The
search for this entity soon began, though
it is important to remember that the exis-
tence of a natural naive state of human
pluripotency similar to that in the mouse
remains a theory, not a proven fact. It is
also important to remember that human
PSCs, whether they originate from the
process of carcinogenesis in vivo (terato-
carcinomas), from embryos, or from
induction of pluripotency by defined fac-
tors, all settle into a similar phenotype or
attractor state, distinct from that of naive
mouse ESCs, even in those instances
where they were established under condi-
tions (e.g. those that involve feeder cells,
serum, and LIF supplementation) that
support (albeit suboptimally) long-term
maintenance of mouse naive ESCs.Cell Stem Cell 15,Why Naive Human PSCs?
It is obviously of fundamental interest
to those studying the biology of pluripo-
tency and comparative development to
know whether there is some universal
naive ground state that exists across spe-
cies. However compelling and important
this concept may be, it is also fair to
question whether there would be any
real practical advantages to having hu-
man naive PSCs.
It has long been noted that the low clon-
ing efficiency of the human PSCs relative
to that of mouse naive cells represents a
barrier to some research protocols, in
particular gene targeting, though new
technologies for genetic manipulation
(TALEN and CRISPR) seem likely to
obviate this difficulty. It is less clear that
growth at clonal density is an essential
attribute for scale-up platforms, a number
of which successfully expand undifferen-
tiated cells in aggregate suspension
cultures. Maintenance of two active X
chromosomes, and X inactivation upon
differentiation, is characteristic of naive
mouse ESCs, and indeed for certain pur-
poses, maintaining this state in the human
cultures would certainly be advanta-
geous. Although theremay be species dif-
ferences in X inactivation, inconsistencies
in human cell lines derived under conven-
tional conditions are certainly problem-
atic. Finally it is generally held that at the
level of the transcriptome and epige-
nome, epiblast stem cells and conven-
tional PSCs display more evidence of
lineage priming (i.e., coexpression of plu-
ripotency and lineage-specific markers)
than naive cells do. This characteristic
has led to the reasonable suggestion
that naive cells, in a more pristine epige-
netic state, might be more amenable to
differentiation intomultiple tissue lineages
than primed cultures of human PSCs orNovember 6, 2014 ª2014 Elsevier Inc. 543
Cell Stem Cell
Forummouse epiblast stem cells would be.
However, there is not much evidence
(apart from in vivo chimera formation) to
show that mouse naive cells are better
at giving rise to differentiated cells than
epiblast stem cells are. By now a vast va-
riety of differentiated tissue cells have
been generated from conventional human
PSCs, and in many cases they have
been shown to be capable of significant
functional maturation. Indeed, products
derived from conventional human ESCs
(and recently iPSCs) are in clinical trials
now for several indications and more are
likely to follow soon. In summary, while it
is of undoubted fundamental interest to
capture human naive PSCs, many bar-
riers to the use of conventional PSCs in
research and therapy have already been
surmounted (Tabar and Studer, 2014),
and the practical advantages that naive
cells might offer are mostly speculative
at present.
Many Roadmaps, Many
Destinations?
Recently published studies describe
multiple pathways (some more convo-
luted than others) to the establishment
of the human naive state (Chan et al.,
2013; Gafni et al., 2013; Takashima
et al., 2014; Theunissen et al., 2014;
Ware et al., 2014). Several of the protocols
begin with an epigenetic rebooting, deliv-
ered through either treatment with histone
deacetylase inhibition or transient expres-
sion of pluripotency factors. Given that
most any differentiated cell in the body
can be reprogrammed to pluripotency
through such manipulation in vitro, it is
not surprising that these tactics should
succeed in nudging PSCs around the
epigenetic landscape. For purposes of
maintenance, most protocols incorporate
the paradigm from Ying and Smith’s land-
mark studies using small-molecule inhibi-
tors of differentiation pathways to provide
strict maintenance of the naive state in
mouse cells. All protocols incorporate
GSK and ERK inhibition with LIF supple-
mentation, though universally this com-
bination alone fails to establish and
maintain human PSCs. Some of the
methods still retain factors that activate
FGF and or Activin/nodal signaling,
though several dispense with these path-
ways altogether. (Few studies take into
account the possibility of autocrine or
paracrine signaling between cells, which544 Cell Stem Cell 15, November 6, 2014 ª2could confound the interpretation of the
data). Several studies, but not all, prove
dependence of the cells on LIF signaling
for maintenance. The data on ERK inhibi-
tion are not inconsistent with a require-
ment for FGF, since the positive effects
of FGF or other tyrosine kinase receptor
signals on human PSC maintenance are
mediated via activation of PI3K/AKT
rather than the MEK/ERK pathway (Singh
et al., 2012). Apart from these commonal-
ities, the various methods employ a
somewhat eclectic set of combinations
of inhibitors of signal transduction ki-
nases, with at least one report (Theunis-
sen et al., 2014) stating that three other
published systems failed to maintain cells
altogether in the authors’ hands.
The key criteria used to assess arrival at
the naive state include morphology, gene
expression, metabolic activity, epigenetic
status (particularly X inactivation in female
lines), and differentiation capacity. Most
studies claim that the human cells in naive
conditions form dome-like mouse ESC
colonies. With respect to gene expres-
sion, Huang et al. (2014) have undertaken
a systems biology survey of these studies.
Some very interesting points emerge from
this work. Active gene networks in human
naive cells resemble those in the human
(but not mouse) blastocyst, while conven-
tional human PSC cultures display a pro-
file that resembles blastocyst outgrowths,
suggestive of adaptation to culture. It is
interesting that the gene networks that
most strongly link naive cells with the
blastocyst are those regulating metabolic
activity. The authors note that the various
culture systems used to maintain naive
and conventional human PSCs in these
studies vary considerably (many of the
studies compare conventional PSC cul-
tures grown in serum or serum replace-
ment to naive cells grown under more
defined conditions). Because basal cul-
ture media components can profoundly
affect both the cell’s metabolism and
epigenetic status, it is important to
consider the role these factors might
play in determining the differences be-
tween naive and conventional states.
The overview of the data indicates clearly
that each human naive state has a distinct
transcriptional profile. Given this, and the
report from Theunissen et al. (2014) indi-
cating that several of the culture systems
for naive state propagation do not even
maintain stem cells in their hands, it014 Elsevier Inc.seems fairly clear that independent confir-
mation on a broad panel of cell lines by
multiple laboratories will be required to
validate whether indeed any of these sys-
tems merits adoption as a common plat-
form for naive human PSC derivation
and propagation.
Several reports show that the naive
conditions shift cells to oxidative meta-
bolism in a manner more similar to that
of mouse ESCs rather than the anerobic
glycolysis seen in conventional human
PSCs. Most reports claim widespread
resetting of the epigenome after transfer
to naive conditions, including a decline
in bivalent histone marks and decreases
in DNA methylation, and there is evi-
dence in some studies for the presence
of two active X chromosomes in female
lines. However, surveys of DNA methyl-
ation across a broad panel of human
PSCs have revealed considerable varia-
tion among cell lines, as have studies of
X inactivation, and both of these epige-
netic features are reported to be subject
to modulation by culture conditions in
conventional human PSC lines. All studies
report considerable improvement in clon-
ing efficiency under naive conditions, but
again, it has been known for some time
that human PSCs grown under conven-
tional conditions can also readily undergo
adaptation to dissociation and survival as
single cells. Finally, none of these studies
really demonstrates that any naive human
PSC has a superior differentiation capac-
ity compared to conventional ESCs, with
the exception of one study showing
some enhancement in PSC ability to
incorporate into the mouse blastocyst
relative to naive cells (Gafni et al., 2013),
and another using naive rhesus monkey
iPSCs that showed substantial engraft-
ment into host mouse embryos (Fang
et al., 2014). This is an assay that mea-
sures not only developmental capacity,
but also the ability to integrate into host
embryonic structures and to respond to
host developmental clues on the mouse
developmental timetable. It will be of in-
terest to see if new cell lines derived
from nonhuman primates are able to inte-
grate into conspecific host embryos to
form chimeras.
The Current State of Naivety
While it is unlikely that we have heard the
last of this matter, it appears that a wide
range of experimental protocols enable
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with features similar, but not identical, to
those of naive mouse ESCs. The resolu-
tion of the fundamental questions of
whether a natural state of naive pluripo-
tency similar to that in the mouse exists
in the primate and whether conventional
human PSCs in fact equate to epiblast
stem cells will need to await further careful
comparative studies of primate preim-
plantation and postimplantation develop-
ment andmore extensive data on de novo
derivation of naive human PSCs. In fact
the few comparative studies that have
addressed signaling pathways controlling
growth and differentiation in the preim-
plantation embryo show fairly clear differ-
ences between human and mouse. One
of the most significant developmental dif-
ferences, pertinent to the generation of
naive epiblast cells, is the ability of mouse,
but not human, embryos to enter
diapause, in which the epiblast exists in
a state of suspended animation. Notably
the only known physiological role of LIF
in preimplantation development is the
maintenance of the epiblast in diapause
(Nichols et al., 2001).
All of these studies of naive human
PSCs have been carried out at a popula-
tion level. Recent single-cell studies of
mouse and human pluripotent cells main-
tained under conditions that support
naive pluripotency (mouse; Morgani
et al., 2013) or strongly suppress sponta-
neous differentiation (human; Hough
et al., 2014) indicate that substantial het-
erogeneity still persists in these popula-
tions. In both cases there is evidence foroscillation of cells between a state in
which pluripotency genes are consistently
expressed at a high level and a state
that is primed for differentiation into the
extraembryonic endoderm lineage (a fate
expected of early epiblast cells). The sin-
gle-cell work argues, perhaps unsurpris-
ingly, that PSCs in culture are inherently
metastable, even when maintained under
conditions that strongly suppress somatic
differentiation.
Indeed, one of the more exciting con-
cepts to emerge from the work on human
naive stem cells is that, given a bit of an
epigenetic shock and some judicious
short-circuiting of signaling pathways, it
is possible to maintain and propagate
entirely new cell states in culture—cell
states that may represent evanescent in-
termediates in embryonic or fetal devel-
opment or somatic tissue lineages, or
even completely synthetic cell states
that do not exist in nature. These new
cellular states may provide facile routes
to the production of specialized tissues
with important therapeutic properties.
This concept is similar to some views of
the process of cellular reprogramming to
pluripotency: clones that are discarded
or ignored as incompletely reprog-
rammed cells may in fact be very inter-
esting intermediates on pathways to new
and different destinations. These altered
cellular states may exist and propagate
in defiance of epigenetic gravity, but there
is nothing really new here. Thirty years of
incredibly productive research using
mouse ESCs has relied on their ability to
do just that.Cell Stem Cell 15,REFERENCES
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